Hospital Infection Therapeutics Market Research Report, 2023

Free Press Release DB | Press Release Date : Dec 7, 2017  Download

Hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal population in healthcare setting and high occurrence of numerous hospital infections.

Increasing incidences of hospital infections, high number of pipeline drug molecules for specific treatment of healthcare associated infections and high unaddressed needs in most of the countries are some of the factors providing ample opportunities for the hospital infection therapeutics market to grow in the coming years.

North America leads the hospital infection therapeutics market followed by Europe. The North America hospital infection therapeutics market leads, due to improved healthcare awareness, high ratio of hospitals as compared to population of the region, increasing count of multi drug resistant microbial pathogens and increase in aging population of the region. Asia-Pacific is growing with an exponential rate, due to increased incidences of hospital infections and high demands of therapeutic drugs in the emerging countries such India and China.

Explore more about “Hospital Infection Therapeutics Market” at:

Hospital acquired infections are caused produced by viral pathogens, fungal and bacterial. Most of the hospital infections crop up from intensive care units. Varied range of hospital infections are being treated by various antimicrobial drugs. The patients staying in the hospitals develop several infections during their treatment.  . The infections are known as hospital-acquired infections or hospital infections. The hospital acquired infections spread in the hospitals, rehabilitation centers, outpatient surgery centers, nursing homes and dialysis centers.

Some of the pipeline drugs available in the market for hospital acquired infections are MK-3415A, Amikacin Inhale, Oritavancin, Surotomycin, Ceftolozane, Dalvance, Plazomicin, Eravacycline, Tedizolid, Delafloxacin, and CAZ AVI. In 2011, according to the centers for disease control and prevention, around 1.6 million hospital acquired infections have been reported from all types of bacteria in US every year. Additionally, in 2013 about 4 million patients were identified with hospital acquired infections in Europe.

Request Report Sample at:

Some of the competitors in the hospital infection therapeutics market are: Cubist Pharmaceuticals, Inc., Actavis PLC, Johnson & Johnson Services, Inc., Bayer AG, GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Pfizer, Inc. and Sanofi.

Contact Person & Company



Vijay Kumar



P&s Market Research

Contact Numbers

Telephone No.



Fax No.


Handphone No.



Website 1


Go To PR Site

Website 2




PR Tags


Hospital Infection Therapeutics Market, Hospital Infection Therapeutics Market Size, Hospital Infection Therapeutics Market Share, Hospital Infection Therapeutics Market Trends,


347, 5th Ave. #1402

10016, New York

United States

United States

Contact The Author

Contact Vijay Kumar

More Press Release From Author

MRI Compatible Patient Monitoring Systems Market is Increasing due to Increasing Prevalence of Chronic Diseases

Free Press Release DB :

Global MRI compatible patient monitoring systems market is growing, due to increasing installation of MRI devices. --> Read This Press Release !

By : Vijay, Kumar ( Jan 17, 2018 )
Category : Business Press Release | Country : United States Press Release

Prefilled Syringes Market - Global Industry Analysis, Size and Future Scope

Free Press Release DB :

Prefilled syringes market was valued at $3,905.1 million in 2014, and it is expected to grow with a CAGR of 12.9% till 2020. --> Read This Press Release !

By : Vijay, Kumar ( Jan 17, 2018 )
Category : Business Press Release | Country : United States Press Release

Advanced Wound Care Market Research Report Analysis, 2022

Free Press Release DB :

Advanced wound care market was valued at $10,659.6 million in 2015, and it is expected to grow at a CAGR of 7.0% during the period 2016-2022. --> Read This Press Release !

By : Vijay, Kumar ( Dec 5, 2017 )
Category : Healthcare Press Release | Country : United States Press Release

Read More Articles From Vijay Kumar


The author of the press releases are solely responsible for the content of their press releases. can't be held liable for the content posted by author. Please check the accuracy of the press release before using the press release. If necessary please contact the author. Thank you.

Report Abuse